|
|
| Journal | Circulation | Geographic
Distribution | Customer
Segments |
|
American Biotech Laboratory |
50'000 |
USA |
22% biophysics,
19% biochemistry,
17% chemistry,
11% biotech |
|
American Laboratory |
70'000 |
USA/Canada |
21% chemistry,
15% environmentals / analytics,
15% pharma |
|
Bio Tech International |
24'000 |
74% Europe,
18% Asia |
12% pharma,
13% molecular biology,
11% biochemistry |
|
Bio-IT World |
|
|
|
|
BioExecutive International |
14'000 |
79% North America,
21% Europe |
53% biopharmaceuticals / biotech,
19% clinical research |
|
BIOforum |
15'000 |
90% DE |
35% pharma,
28% biotech,
12% university |
|
BIOforum Europe |
26'000 |
20% DE,A,CH,
18% UK,
22% Scandinavia,
11% France |
35% biotech,
28% pharma/food/cosmetics,
12% university |
|
Biopharm International |
30'000 |
74% North America,
17% Europe,
7% Asia |
33% biopharm,
23% pharma,
10% research |
|
BioProcess International |
30'000 |
67% USA/CDN,
33% EU |
41% biopharm,
10% clinical research,
9% biotech |
|
BioScience Technology |
55'000 |
USA |
22% university,
18% private research,
17% pharma,
16% biotech |
|
BioTechniques |
80'000 |
76% USA/Cdn,
20% Europe,
2% Asia |
16% molecular biology,
14% biochemistry,
12% cell biology,
11% microbiology |
|
Biotechnologies & Finances |
|
|
|
|
cav - chemie-anlagen + verfahren |
35'000 |
D/CH/A |
55% chemistry/pharma,
12% plant manufacture |
|
Chemanager |
43'000 |
D/CH/A |
51% chemistry,
33% biotech |
|
Chemanager Europe |
15'000 |
18% UK,
25% D/CH/A,
13% F,
9% Benelux,
8% Eastern Europe,
8% I,
6% Scandinavia,
5% E/P |
51% chemistry,
33% biotech |
|
Chemie plus |
13'000 |
CH |
|
|
Chemische Rundschau |
12'000 |
CH |
59% chemistry,
14% biotech |
|
CITplus |
26'000 |
D/CH/A |
41% chemistry,
30% engineering,
9% pharma |
|
clb - Chemie in Labor und Biotechnik |
5'000 |
D/CH/A |
|
|
Contract Pharma |
20'000 |
80% USA |
39% pharma,
10% CMO,
19% CRO |
|
Contract Services Europe |
|
|
|
|
cpp chemical plants + processing |
25'000 |
67% Europe,
25% Asia,
7% Americas |
55% chemistry / pharma,
12% plants |
|
Drug Discovery & Development |
35'000 |
95% USA |
44% pharma,
23% biotech,
7% biopharm |
|
European Biotechnology News |
15'000 |
91% Europe |
35% pharma,
19% suppliers,
18% university,
15% research |
|
European Pharma Manufacturer |
13'000 |
30% UK,
14% F,
13% D,
11% Scandinavia |
|
|
Forschung und Diagnostik |
8'000 |
D/CH/A |
42% medical,
20% pharma |
|
GEN |
80'000 |
70% USA |
29% cell culture,
28% genomics,
28% separation |
|
GIT Labor-Fachzeitschrift |
25'000 |
D/CH/A |
35% chemistry,
18% pharma,
11% university,
10% biotech |
|
GIT Laboratory Journal Europe |
27'000 |
22% UK/IR,
20% D/A/CH,
13% Scandinavia,
11% F,
10% Benelux |
35% chemistry,
19% pharm,
6% food,
5% biotech |
|
GIT ReinraumTechnik |
10'000 |
D/CH/A |
25% pharma,
11% food,
8% biotech |
|
GIT Separation |
25'000 |
D/CH/A |
39% chemistry,
21% pharma,
13% biotech,
13% university |
|
GIT Steriltechnik |
10'000 |
D/CH/A |
30% pharma,
21% biotech,
17% food,
13% medical,
9% cosmetic |
|
Industrial Biotechnology |
4'000 |
|
|
|
International Labmate |
38'000 |
78% EU,
21% middle east |
46% industry,
37% hospital,
14% university |
|
Journal of Biomoldecular Screening |
|
|
|
|
Journal of the Association of Lab Automation |
|
|
|
|
Lab Asia |
25'000 |
17% China,
11% India,
10% Malaysia,
8% Taiwan,
8% Korea,
7% Australia |
52% industry,
37% hospital,
8% government |
|
LabBusiness |
25'000 |
Canada |
31% chemical/pharma,
29% environmental,
27% food |
|
Labmate UK |
10'000 |
UK |
49% industry,
32% hospitals |
|
Labo |
5'000 |
D/CH/A |
21% chemistry / biotech,
15% university |
|
Laboratorio y Analisis |
27'000 |
36% Mexico,
14% Argentina,
9% Brazil,
8% Colombia,
7% Chile,
4% Venezuela |
31% chemistry,
20% food,
15% medical,
10% processing |
|
Laborjournal |
258000 |
D/CH/A |
29% universities,
26% industry |
|
Laborpraxis |
23'000 |
D/CH/A |
39% chemistry / pharma,
13% university,
5% clinical labs |
|
LaborpraxisChina |
10'000 |
|
|
|
Laborwelt |
20'000 |
D/CH/A |
37% university,
23% research,
13% pharma / biotech |
|
Lebensmittel & Biotechnologie |
2'000 |
80% A,
|
|
|
Nature |
60'000 |
55% Americas,
30% Europe,
15% Asia |
58% university,
12% industries |
|
Nature biotech |
17'000 |
90% North-America |
23% molecular biology,
13% genomics,
8% microbiology |
|
Nature Cell Biology |
3'000 |
41% Americas,
39% Europe |
|
|
Nature Chemical Biology |
|
|
|
|
Nature Drug Discovery Reviews |
10'000 |
55% Americas,
35% Europe,
10% Asia |
25% biotech,
21% pharma,
18% university,
11% consultants |
|
Nature Genetics |
6'000 |
56% Americas,
18% Europe |
50% research,
40% medical,
10% pharma / biotech |
|
Nature Immunology |
3'000 |
46% Americas,
20% Europe |
|
|
Nature Medicine |
11'000 |
58% USA,
17% Europe |
70% university / medical,
29% pharma / biotech |
|
Nature Methods |
60'000 |
72% USA,
22% Europe |
54% pharma / biotech,
46% university |
|
Noticias tecnicas |
26‘000 |
78% South America,
22% E |
21% chemistry,
13% biochemistry,
10% analytics,
10% food,
10% biotech |
|
PDA Letter |
10'000 |
|
48% pharma,
23% biopharma,
11% consultants |
|
Pharma + Food |
10'000 |
D/CH/A |
45% pharma,
15% food,
6% engineering |
|
Pharma International |
|
|
|
|
Pharma Manufacturing |
5'000 |
33% UK,
10% D/CH/A,
7%I,
5% Ost-EU |
80% pharma,
20% suppliers |
|
Pharma Processing |
31‘000 |
USA |
79% pharma,
6% medical,
6% consulting,
5% university |
|
Pharmaceutical Engineering |
21'000 |
62% USA,
7% UK,
|
28% engineering,
28% pharma,
10% biotech,
9% supplier |
|
Pharmaceutical Science & Technology Today |
2'000 |
51% Europe,
37% USA,
12% Asia |
62% pharma / biotech,
24% university |
|
Pharmaceutical Technology |
34'000 |
USA |
68% pharma / biopharma,
7% research,
6% university |
|
Pharmaceutical Technology Asia |
5'000 |
27% China,
24% Japan,
9% Korea,
7% India,
5% AUS,
|
|
|
Pharmaceutical Technology Europe |
18‘000 |
21% UK,
17% D/CH/A,
13% F,
10% Scandinavia,
7% I,
6% E,
5% NL,
5% Eastern Europe |
69% pharma,
11% contract services,
7% medical |
|
Pristine Processing |
20'000 |
USA |
36% pharma,
14% biotech,
11% food |
|
Process |
24'000 |
D/CH/A |
50% chemistry / pharma,
29% engineering |
|
Process China |
30'000 |
|
|
|
Process PharmaTEC |
11'000 |
D/CH/A |
46% pharma / chemistry,
13% food,
10% engineering,
9% university,
8% research |
|
Process PharmaTEC international |
15'000 |
26%D/CH/A,
16% Americas,
11% Asia,
8% I,
5% Scandinavia,
5% I |
46% pharma / chemistry,
13% food,
10% engineering,
9% university,
8% research |
|
Process worldwide |
25'000 |
|
|
|
Schreening - Trends in Drug Discovery |
10'000 |
39% D/CH/A,
24% UK,
13% F/B,
12% Scandinavia |
59% pharma,
20% biotech,
15% research |
|
Transkript |
10‘000 |
D/CH/A |
28% biotech,
25% university,
17% suppliers,
18% research |
|
UK Laboratory |
17‘500 |
UK |
18% analytics,
14% chemistry,
9% biochemistry,
7% biotech,
7% pharma |
|
|
|
